FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
Get Alerts HRTX Hot Sheet
Join SI Premium – FREE
Below is the FDA's approval letter Heron Therapeutics' (Nasdaq: HRTX) SUSTOL:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Heron Therapeutics (HRTX) PT Raised to $5 at Needham to reflect strong sales trends
- Intellia Therapeutics (NTLA) doses first patient in Phase 3 MAGNITUDE Study of NTLA-2001
- Natera (NTRA) announces phase III trial of signatera to treat stage II colorectal cancer in France
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!